![CG Oncology Inc](/common/images/company/N_CGON.png)
IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
– Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine and featured at ASCO 2024 – – 54% complete response (CR) rate in the...
IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First...
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.18 | 13.6200716846 | 30.69 | 35.55 | 30.69 | 291439 | 32.79999524 | CS |
4 | 0.41 | 1.18978525827 | 34.46 | 35.55 | 29.26 | 550990 | 32.09056497 | CS |
12 | -0.14 | -0.399885746929 | 35.01 | 46.99 | 25.77 | 662094 | 33.07005103 | CS |
26 | 5.87 | 20.2413793103 | 29 | 50.23 | 25.77 | 675619 | 36.27879615 | CS |
52 | 5.87 | 20.2413793103 | 29 | 50.23 | 25.77 | 675619 | 36.27879615 | CS |
156 | 5.87 | 20.2413793103 | 29 | 50.23 | 25.77 | 675619 | 36.27879615 | CS |
260 | 5.87 | 20.2413793103 | 29 | 50.23 | 25.77 | 675619 | 36.27879615 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.